Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MSCRAMMs on the line

Inhibitex Inc. started its first pivotal trial last week. If positive, the trial will not only provide the company with its first product, but also go a long way in validating its raison d'etre - which is entirely based on microbial surface components recognizing adhesive matrix molecules (MSCRAMMs). But investors will have to

Read the full 536 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers